MONDAY, Jan. 14 (HealthDay News) -- Black Americans continue to distrust medical research and clinical trials, apparently a lasting legacy of the infamous Tuskegee experiment which was shut down more than three decades ago, a new study shows.
Ironically, such attitudes are keeping minorities from participating in current clinical trials that could save their lives, the researchers added.
"We found that minorities are 200 percent more likely to perceive harm coming from participating in research," said senior study author Dr. Neil Powe, a professor of medicine at Johns Hopkins School of Medicine in Baltimore.
While previous studies had shown that black Americans and other minorities are less likely to be enrolled in clinical trials, this study, appearing in Jan. 14 online issue of Medicine, helps explain why.
"This is new knowledge, obtained with appropriate methods in a large sample," said Dr. William Cunningham, a professor of medicine and public health at the UCLA School of Medicine. "This study provides direct evidence that distrust of researchers explains the lower participation of blacks in cardiovascular prevention trials research. This looks like an important study."
"This provides a database to support what we think is going on with respect to concerns of the minority community," said Dr. James Powell, principal investigator of Project IMPACT (Increase Minority Participation and Awareness in Clinical Trials). The project is a program of the National Medical Association, which represents black physicians and their patients. "Mistrust comes up not only with respect to clinical trials, but also with respect to interacting with the medical establishment. This leads to people not seeing a physician when they really need to."
Black Americans tend to be under-represented in clinical trials, which are responsible for most advances in medicine.
This discrepancy is particularly unfortunate, because not only do black Americans suffer disproportionately from many health conditions, they often experience illnesses differently and respond differently to medications, making race-specific trials even more crucial, the researchers noted.
"We're concerned that the lack of minority representation in clinical trials may perpetuate health disparities," Powell said.
Previous studies have shown that this under-representation is, in fact, due to individuals' unwillingness to participate, as opposed to researchers' exclusion of minorities.
And this unwillingness is widely thought to be due to the legacy of Tuskegee and other such research. The government-sponsored Tuskegee Study, named after a town in Alabama where participants were recruited, enrolled several hundred poor, black sharecroppers, telling them that they would receive drugs to treat their syphilis infections. But lifesaving drugs were purposely withheld so the "natural" course of the disease could be observed. The experiment was shut down after a leak to the press in 1972.
In this latest study, Powe and his colleagues conducted a random survey of 717 outpatients at 13 cardiology and general medicine clinics in Maryland. Thirty-six percent of participants were black, the rest white.
After an in-depth explanation by a physician (either black or white), each participant was asked to enroll in a mock trial of a cardiovascular drug.
Only 27 percent of black American respondents were willing to participate, versus 39 percent of whites.
Among the study's other findings:
When the element of distrust was removed from the equation, the proportions of blacks and whites willing to enroll equalized to about a third of those sampled in both racial groups.
The good news is that there are ways to remedy the situations.
"One is physician or researcher relationships and interactions, that physicians and researchers should be taking the time to talk to patients and communicate with them explaining the risk of being involved in medical research and dispelling myths about participating in research," Powe said. "It's hard to do in a busy medical environment today but necessary."
Academic medical centers need also to build relationships that engender trust with the community, even including community members in designing research studies.
Finally, Powe said, patients tend to trust physicians of the same race. "One big issue is that there are not enough minority physicians, so that's a societal remedy we all have to think about," Powe said.
Some 12 percent of the U.S. population is black, but only 4 percent of physicians are black.
The National Cancer Institute has more on minority participation (or lack thereof) in clinical trials.
SOURCES: Neil R. Powe, M.D., M.P.H., M.B.A., professor, medicine, Johns Hopkins School of Medicine, Baltimore; William E. Cunningham, M.D., professor, medicine and public health, UCLA School of Medicine, Los Angeles; James Powell, M.D., principal investigator, Project Impact Program, National Medical Association; Jan. 14, 2008, Medicine